Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Limited information is currently available on ATP128, a putative recombinant vaccine (Aug, 2019).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ATP128||ATP128 is a chimeric protein vaccine that potentially modify antigen presentation of dendritic cells, leading to activation of immune response against tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04046445||Phase Ib/II||ATP128 + BI 754091 ATP128||Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)||Recruiting|